|
1
|
Mao T, Yan Q, Zhou F and Shen YZ:
Isolation and identification of berberine from cell cultures of
Coptis chinensis. Chin J Biotechnol. 13:193–199. 1997.PubMed/NCBI
|
|
2
|
Ríos JL, Francini F and Schinella GR:
Natural products for the treatment of Type 2 diabetes mellitus.
Planta Med. 81:975–994. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sun SF, Zhao TT, Zhang HJ, Huang XR, Zhang
WK, Zhang L, Yan MH, Dong X, Wang H, Wen YM, et al: Renoprotective
effect of berberine on type 2 diabetic nephropathy in rats. Clin
Exp Pharmacol Physiol. 42:662–670. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Di Pierro F, Bellone I, Rapacioli G and
Putignano P: Clinical role of a fixed combination of standardized
Berberis aristata and Silybum marianum extracts in diabetic and
hypercholesterolemic patients intolerant to statins. Diabetes Metab
Syndr Obes. 8:89–96. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chang W, Chen L and Hatch GM: Berberine as
a therapy for type 2 diabetes and its complications: From mechanism
of action to clinical studies. Biochem Cell Biol. 93:479–486. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lan J, Zhao Y, Dong F, Yan Z, Zheng W, Fan
J and Sun G: Meta-analysis of the effect and safety of berberine in
the treatment of type 2 diabetes mellitus, hyperlipemia and
hypertension. J Ethnopharmacol. 161:69–81. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dong Y, Chen YT, Yang YX, Zhou XJ, Dai SJ,
Tong JF, Shou D and Li C: Metabolomics study of type 2 diabetes
mellitus and the antidiabetic effect of berberine in zucker
diabetic fatty rats using Uplc-ESI-Hdms. Phytother Res. 30:823–828.
2016. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yi Q, He XE, Luo KF, Zhang GS, Liu YH, Xue
Q, Hou N, Chen WL and Luo JD: Protection of long-term treatment
with huang-lian-jie-du-tang on vascular endothelium in rats with
type 2 diabetes mellitus. Curr Ther Res Clin Exp. 73:174–185. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li CB, Li XX, Chen YG, Gao HQ, Bu PL,
Zhang Y and Ji XP: Huang-lian-jie-du-tang protects rats from
cardiac damages induced by metabolic disorder by improving
inflammation-mediated insulin resistance. PLoS One. 8:e675302013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu JS, Shi R, Lu X, Ma YM and Cheng NN:
Combination of active components of Xiexin decoction ameliorates
renal fibrosis through the inhibition of NF-κB and TGF-β1/Smad
pathways in db/db diabetic mice. PLoS One. 10:e01226612015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang Z, Wang L, Zhang F and Li Z:
Evaluating the antidiabetic effects of Chinese herbal medicine:
Xiao-Ke-An in 3T3-L1 cells and KKAy mice using both conventional
and holistic omics approaches. BMC Complement Altern Med.
15:2722015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chang YX, Ge AH, Donnapee S, Li J, Bai Y,
Liu J, He J, Yang X, Song LJ, Zhang BL and Gao XM: The
multi-targets integrated fingerprinting for screening anti-diabetic
compounds from a Chinese medicine Jinqi Jiangtang Tablet. J
Ethnopharmacol. 164:210–222. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zarei A, Changizi-Ashtiyani S, Taheri S
and Ramezani M: A quick overview on some aspects of
endocrinological and therapeutic effects of Berberis vulgaris L.
Avicenna J Phytomed. 5:485–497. 2015.PubMed/NCBI
|
|
14
|
Pang B, Zhao LH, Zhou Q, Zhao TY, Wang H,
Gu CJ and Tong XL: Application of berberine on treating type 2
diabetes mellitus. Int J Endocrinol. 2015:9057492015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pang B, Yu XT, Zhou Q, Zhao TY, Wang H, Gu
CJ and Tong XL: Effect of rhizoma coptidis (Huang Lian) on treating
diabetes mellitus. Evid Based Complement Alternat Med.
2015:9214162015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li F, Zhao YB, Wang DK, Zou X, Fang K and
Wang KF: Berberine relieves insulin resistance via the cholinergic
anti-inflammatory pathway in HepG2 cells. J Huazhong Univ Sci
Technolog Med Sci. 36:1–69. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Geng FH, Li GH, Zhang X, Zhang P, Dong MQ,
Zhao ZJ, Zhang Y, Dong L and Gao F: Berberine improves mesenteric
artery insulin sensitivity through up-regulating insulin
receptor-mediated signaling in diabetic rats. Br J Pharmacol.
173:1569–1579. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lu L, Zhijian H, Lei L, Wenchuan C and
Zhimin Z: Berberine in combination with insulin has additive
effects on titanium implants osseointegration in diabetes mellitus
rats. Evid Based Complement Alternat Med. 2015:8242592015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yu Y, Hao G, Zhang Q, Hua W, Wang M, Zhou
W, Zong S, Huang M and Wen X: Berberine induces GLP-1 secretion
through activation of bitter taste receptor pathways. Biochem
Pharmacol. 97:173–177. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou J, Du X, Long M, Zhang Z, Zhou S,
Zhou J and Qian G: Neuroprotective effect of berberine is mediated
by MAPK signaling pathway in experimental diabetic neuropathy in
rats. Eur J Pharmacol. 774:87–94. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tang LQ, Ni WJ, Cai M, Ding HH, Liu S and
Zhang ST: The renoprotective effects of berberine and its potential
impact on the expression of β-arrestins and ICAM-1/VCAM-1 in
streptozocin induced-diabetic nephropathy rats. J Diabetes.
November 3–2015.(Epub ahead of print).
|
|
22
|
Friedemann T, Schumacher U, Tao Y, Leung
AK and Schröder S: Neuroprotective activity of coptisine from
coptis Chinensis (Franch). Evid Based Complement Alternat Med.
2015:8273082015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang X, Zhao Y, Xu J, Xue Z, Zhang M,
Pang X, Zhang X and Zhao L: Modulation of gut microbiota by
berberine and metformin during the treatment of high-fat
diet-induced obesity in rats. Sci Rep. 5:144052015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xie W, Gu D, Li J, Cui K and Zhang Y:
Effects and action mechanisms of berberine and Rhizoma coptidis on
gut microbes and obesity in high-fat diet-fed C57BL/6J mice. PLoS
One. 6:e245202011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu X, Li Y, Wang Q, Li W and Feng Y:
Effects of berberine and pomegranate seed oil on plasma
phospholipid metabolites associated with risks of type 2 diabetes
mellitus by U-HPLC/Q-TOF-MS. J Chromatogr B Analyt Technol Biomed
Life Sci. 1007:110–120. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chang W, Li K, Guan F, Yao F, Yu Y, Zhang
M, Hatch GM and Chen L: Berberine pretreatment confers
cardioprotection against ischemia-reperfusion injury in a rat model
of type 2 diabetes. J Cardiovasc Pharmacol Ther. 21:486–494. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dai P, Wang J, Lin L, Zhang Y and Wang Z:
Renoprotective effects of berberine as adjuvant therapy for
hypertensive patients with type 2 diabetes mellitus: Evaluation via
biochemical markers and color Doppler ultrasonography. Exp Ther
Med. 10:869–876. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chang W, Zhang M, Meng Z, Yu Y, Yao F,
Hatch GM and Chen L: Berberine treatment prevents cardiac
dysfunction and remodeling through activation of 5′-adenosine
monophosphate-activated protein kinase in type 2 diabetic rats and
in palmitate-induced hypertrophic H9c2 cells. Eur J Pharmacol.
769:55–63. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jiang SJ, Dong H, Li JB, Xu LJ, Zou X,
Wang KF, Lu FE and Yi P: Berberine inhibits hepatic gluconeogenesis
via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced
diabetic rats. World J Gastroenterol. 21:7777–7785. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jhong CH, Riyaphan J, Lin SH, Chia YC and
Weng CF: Screening alpha-glucosidase and alpha-amylase inhibitors
from natural compounds by molecular docking in silico. Biofactors.
41:242–251. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chang W, Chen L and Hatch GM: Berberine
treatment attenuates the palmitate-mediated inhibition of glucose
uptake and consumption through increased 1,2,3-triacyl-sn-glycerol
synthesis and accumulation in H9c2 cardiomyocytes. Biochim Biophys
Acta. 1864:352–362. 2016. View Article : Google Scholar
|
|
32
|
Pirillo A and Catapano AL: Berberine, a
plant alkaloid with lipid- and glucose-lowering properties: From in
vitro evidence to clinical studies. Atherosclerosis. 243:449–461.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xue M, Zhang L, Yang MX, Zhang W, Li XM,
Ou ZM, Li ZP, Liu SH, Li XJ and Yang SY: Berberine-loaded solid
lipid nanoparticles are concentrated in the liver and ameliorate
hepatosteatosis in db/db mice. Int J Nanomedicine. 10:5049–5057.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang Y, Chang X, Song X, Chen C, Chen H,
Lu Z, Gao X and Lu D: Berberine reverses abnormal expression of
L-type pyruvate kinase by DNA demethylation and histone acetylation
in the livers of the non-alcoholic fatty disease rat. Int J Clin
Exp Med. 8:7535–7543. 2015.PubMed/NCBI
|
|
35
|
Zhang J, Tang H, Deng R, Wang N, Zhang Y,
Wang Y, Liu Y, Li F, Wang X and Zhou L: Berberine suppresses
adipocyte differentiation via decreasing Creb transcriptional
activity. PLoS One. 10:e01256672015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang Z, Wu J, Zhou Q, Wang Y and Chen T:
Berberine nanosuspension enhances hypoglycemic efficacy on
streptozotocin induced diabetic C57BL/6 mice. Evid Based Complement
Alternat Med 2015. 2397492015.
|
|
37
|
Liu C, Wang Z, Song Y, Wu D, Zheng X, Li
P, Jin J, Xu N and Li L: Effects of berberine on amelioration of
hyperglycemia and oxidative stress in high glucose and high fat
diet-induced diabetic hamsters in vivo. Biomed Res Int.
2015:3138082015.PubMed/NCBI
|
|
38
|
Cui E, Zhi X, Chen Y, Gao Y, Fan Y, Zhang
W, Ma W, Hou W, Guo C and Song X: Coptis chinensis and myrobalan
(Terminalia chebula) can synergistically inhibit inflammatory
response in vitro and in vivo. Evid Based Complement Alternat Med.
2014:5101572014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang O, Cai K, Pang S, Wang T, Qi D, Zhu
Q, Ni Z and Le Y: Mechanisms of glucose-induced expression of
pancreatic-derived factor in pancreatic beta-cells. Endocrinology.
149:672–680. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gastaldelli A, Ferrannini E, Miyazaki Y,
Matsuda M, Mari A and DeFronzo RA: Thiazolidinediones improve
beta-cell function in type 2 diabetic patients. Am J Physiol
Endocrinol Metab. 292:E871–E883. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Guardado-Mendoza R, Davalli AM, Chavez AO,
Hubbard GB, Dick EJ, Majluf-Cruz A, Tene-Perez CE, Goldschmidt L,
Hart J, Perego C, et al: Pancreatic islet amyloidosis, beta-cell
apoptosis, and alpha-cell proliferation are determinants of islet
remodeling in type-2 diabetic baboons. Proc Natl Acad Sci USA.
106:13992–13997. 2009; View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Andreone T, Meares GP, Hughes KJ, Hansen
PA and Corbett JA: Cytokine-mediated β-cell damage in
PARP-1-deficient islets. Am J Physiol Endocrinol Metab.
303:E172–E179. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Radzi SF Muhd, Rückert C, Sam SS, Teoh BT,
Jee PF, Phoon WH, Abubakar S and Zandi K: Detection of Langat virus
by TaqMan real-time one-step qRT-PCR method. Sci Rep. 5:140072015.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
